Langford Arch
Unit 2A London Road Pampisford
Cambridge CB22 3FX
United Kingdom
44 1223 497 700
https://www.sareum.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Timothy John Mitchell Ph.D. | Founder, CEO & Executive Director | 207.85k | N/A | 1960 |
Dr. John Charles Reader Ph.D. | Founder, Chief Scientific Officer & Executive Director | 205.8k | N/A | 1967 |
Mr. Clive H. W. Birch F.C.A. | Senior Independent Non-Executive Director & Secretary | 25k | N/A | 1954 |
Alexandra Harrison | Head of IR | N/A | N/A | N/A |
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases. Its also developing SDC-1802, a TYK2/JAK1 inhibitor, which is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor, which has completed Phase II clinical trials that targets cancer cell replication and DNA damage repair mechanisms. The company was incorporated in 2004 and is headquartered in Cambridge, the United Kingdom.
Sareum Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.